Ibrance is primarily prescribed for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. It is often recommended for women who have progressed following endocrine therapy. Men with the same type of breast cancer may also benefit from the treatment.
